97. Ulcerative colitis Clinical trials / Disease details

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

15 trials found

diseases per page:

Showing 1 to 10 of 15 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000043165	2021/02/01	31/01/2021	Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilarCT-P ...	Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilarCT-P ...	Crohn's disease, Ulcerative colitis, IBDU	witching from originator infliximab to infliximab biosimilar CT-P13	Fukuoka University Chikushi Hospital	NULL	Pending	Not applicable	Not applicable	Male and Female	220	Not selected	Japan
2	EUCTR2019-003662-40-DE (EUCTR)	18/12/2019	22/10/2019	Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and ...	Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and ...	MedDRA version: 20.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System ...	Trade Name: Amgevita 40 mg Injektionslösung in einer Fertigspritze INN or Proposed INN: ADALIMUMAB Tra ...	Universitätsklinikum Erlangen	NULL	Not Recruiting			Female: yes Male: yes	82	Phase 4	Germany
3	NCT04131322 (ClinicalTrials.gov)	October 10, 2019	10/10/2019	Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.	Loss of Response of Adalimumab BiosimilarCompared With the Loss of Response of Adalimumab Original: ...	Crohn Disease;Ulcerative Colitis	Drug: Amgevita 40Mg Solution for Injection;Drug: HUMIRA 40Mg Solution for Injection	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	NULL	Terminated	18 Years	N/A	All	24	Phase 4	Spain
4	NCT04018599 (ClinicalTrials.gov)	July 15, 2019	11/7/2019	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, a ...	Rheumatoid Arthritis;Polyarticular Juvenile Idiopathic Arthritis;Psoriatic Arthritis;Ankylosing Spon ...	Drug: 40 mg MSB11022	Fresenius Kabi SwissBioSim GmbH	PRA Health Sciences	Completed	18 Years	55 Years	All	216	Phase 1	United States
5	EUCTR2019-000717-37-ES (EUCTR)	27/06/2019	28/06/2019	Loss of response of the Adalimumba biosimilar compared with the original drug	LOSS OF RESPONSE OF THE ADALIMUMAB BIOSIMILARCOMPARED WITH THE LOSS OF RESPONSE OF THE ADALIMUMAB OR ...	Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis;Therapeutic area: Diseases [C] - ...	Trade Name: AMGEVITA® Product Name: AMGEVITA (Adalimumab biosimilar) Trade Name: HUMIRA ® Product Name: ...	Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)	NULL	Not Recruiting			Female: yes Male: yes	136	Phase 4	Spain
6	NCT03884439 (ClinicalTrials.gov)	March 18, 2019	4/3/2019	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or ...	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or ...	Crohn's Disease;Ulcerative Colitis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Recruiting	N/A	N/A	All	300		Japan
7	NCT03729674 (ClinicalTrials.gov)	November 26, 2018	11/10/2018	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Rheumatoid Arthritis;Ankylosing Spondylitis;Ulcerative Colitis;Crohn's Disease	Drug: Biosimilar;Drug: Originator (legacy) drug	McGill University Health Centre/Research Institute of the McGill University Health Centre	Université de Sherbrooke;Institut de rhumatologie de Montréal;Hospital for Special Surgery, New York ...	Recruiting	18 Years	N/A	All	800		Canada
8	EUCTR2018-001546-33-GB (EUCTR)	11/07/2018	14/05/2018	The effects of switching one drug, used to treat either Ulcerative Colitis (UC) or Crohn’s disease ( ...	IBD Biosimilar to Biosimilar Infliximab Switching Study - iBiSS v1.0	Inflammatory Bowel Disease in particular Crohn's Disease and Ulcerative Colitis MedDRA version: 20.1 ...	Trade Name: Flixabi Product Name: Flixabi INN or Proposed INN: Infliximab	University Southampton Hospital NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	200	Phase 4	United Kingdom
9	JPRN-UMIN000027465	2017/05/29	24/05/2017	Efficacy and safety of the biosimilar Infliximab in the patients with ulcerative colitis	Efficacy and safety of the biosimilarInfliximab in the patients with ulcerative colitis - Efficacy a ...	ulcerative colitis	Infliximab(5mg/kg, every 8 weeks, for 12 months) Biosimilar Infliximab(5mg/kg, every 8 weeks, for 12 ...	University of Toyama	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan
10	EUCTR2016-002061-54-IT (EUCTR)	13/10/2016	15/11/2018	Switch between originator infliximab (Remicade®) and biosimilarinfliximab (Remsima®) in the treatmen ...	Switch between originator infliximab (Remicade®) and biosimilarinfliximab (Remsima®) in the treatmen ...	Rheumatoid arthritis, seronegative spondylo arthritis,Crohn's Disease, Ulcerative Colitis MedDRA ver ...	Trade Name: REMSIMA- 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - F ...	UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI	NULL	Not Recruiting			Female: yes Male: yes	250	Phase 4	Italy

First Previous1 2Next Last